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Development of an ANN optimized mucoadhesive buccal tablet 
containing flurbiprofen and lidocaine for dental pain
A novel mucoadhesive buccal tablet containing flurbipro-
fen (FLB) and lidocaine HCl (LID) was prepared to relieve 
dental pain. Tablet formulations (F1-F9) were prepared us-
ing variable quantities of mucoadhesive agents, hydroxy-
propyl methyl cellulose (HPMC) and sodium alginate (SA). 
The formulations were evaluated for their physicochemical 
properties, mucoadhesive strength and mucoadhesion 
time, swellability index and in vitro release of active agents. 
Release of both drugs depended on the relative ratio of 
HPMC:SA. However, mucoadhesive strength and mucoad-
hesion time were better in formulations, containing higher 
proportions of HPMC compared to SA. An artificial neural 
network (ANN) approach was applied to optimise formula-
tions based on known effective parameters (i.e., mucoadhe-
sive strength, mucoadhesion time and drug release), which 
proved valuable. This study indicates that an effective buc-
cal tablet formulation of flurbiprofen and lidocaine can be 
prepared via an optimized ANN approach.
Keywords: dental pain, mucoadhesion time, mucoadhesive 
strength, buccal tablet, artificial neural network
Dental pathologies/disorders are usually associated with inflammation and moderate 
to severe pain (1). These are managed using analgesics alone or in combination with a vari-
ety of other drugs, e.g., antibiotics, local anaesthetics, non-steroidal anti-inflammatory drugs 
(NSAIDs) and cyclooxygenase-2 (COX-2) inhibitors (2, 3). Among analgesics, opioids and 
NSAIDs are commonly used to control acute dental pain. Opioids work by blocking nocic-
eptors and are considered superior to NSAIDs. However, due to adverse drug reactions and 
psychological adherence, opioids require professional supervision, which restricts their use 
(4). NSAIDs, at higher doses, are usually considered the drugs of choice in dental pain (5). 
Among NSAIDs, flurbiprofen (FLB), a propionic acid derivative, is a drug used to treat acute 
pain associated with dental pathology (6, 7). For FLB, the recommended maximum daily 
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An analgesic drug can also be combined with a local anaesthetic for the effective 
control of dental pain (9). Lidocaine (LID), an amide derivative, is a safer anaesthetic agent 
that possesses a mild local analgesic effect (10). The efficacy of combinatorial FLB and LID 
therapy has already been established for the propofol injection induced pain (11).
Local administration of these drugs, as a buccal dosage, can provide an effective route 
for treating dental pain (12). Over the last decade, extensive progress has been made in the 
development of buccal dosage forms (1). The buccal dosage form can be an attractive option 
to deliver drug locally with further advantages including fewer systemic adverse effects 
compared to conventional dosage forms, avoiding the first pass effect and oral enzymatic 
degradation (13, 14). The present study aims to formulate a mucoadhesive buccal dosage 
form to deliver FLB and LID concomitantly. This is achieved by using different proportions 
of mucoadhesive agents such as HPMC and SA. The formulation was optimized using an 
artificial neural network (ANN) approach based on mucoadhesive strength, mucoadhe-
sion time and drug release as desired attributes.
EXPERIMENTAL
LID and FLB were obtained on an in-kind basis from Gufic Biosciences Limited, La-
hore, Pakistan, and Sun Pharmaceuticals, Lahore, Pakistan, respectively. HPMC, Carbopol 
(CP), sodium alginate (SA) and mannitol were obtained from Glow Scientific Traders, La-
hore, Pakistan. HPLC grade methanol and acetonitrile from Merck were obtained at the 
local market.
Nine tablet formulations (assigned as F1 to F9) were prepared using standard doses of 
LID (20 mg) and FLB (100 mg) and varying quantities of mucoadhesive agents (HPMC, SA), 
as given in Table I. Other excipients such as magnesium stearate (lubricant), CP (gelling 



















F1 20 100 2 5 7 10 60 296
F2 20 100 2 5 7 20 55 291
F3 20 100 2 5 7 30 50 286
F4 20 100 2 5 7 40 45 281
F5 20 100 2 5 7 50 40 276
F6 20 100 2 5 7 60 35 271
F7 20 100 2 5 7 70 30 266
F8 20 100 2 5 7 75 25 266
F9 20 100 2 5 7 80 20 266
F10a 20 100 2 5 7 90 10 266
a ANN predicted optimized formulation
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agent) (15) and sucralose (sweetener) (16) were used in fixed quantities. Mannitol was used 
as a filler (17) to contribute towards the desired mass. All ingredients were mixed using a 
mortar and pestle, and tablets were prepared by the direct compression method using a 
single punch tablet machine (Okeda Chem. Co. Ltd.) applying a force of 2 tons for 20 s.
Physicochemical investigation of tablet formulations
Tablet formulations were tested for hardness, mass variation, friability, surface pH, 
mucoadhesive strength, mucoadhesion time, swellability index and in vitro release of both 
drugs. The hardness, mass variation and friability of tablet formulations were tested by 
the standard methods described in the BP (2011).
Surface pH
Surface pH was assessed by placing a tablet from each formulation in a petri dish 
containing 0.1 mol L–1 phosphate buffer (pH 6.8) for 2 h. The pH was measured using a 
digital pH meter electrode on the tablet surface (18).
In vitro mucoadhesion time
An apparatus was devised for the measurement of in vitro mucoadhesion time. One 
face of formulated tablets was wetted with 50 µL phosphate buffer solution (pH 6.8) and 
pressed gently for 20 seconds on freshly cut rabbit mucosa supported by a glass slide. The 
slide was then placed, at an angle of about 45°, in a beaker containing 800 mL of phosphate 
buffer (pH 6.8), maintained at 37 °C. The solution was mechanically stirred at a speed of 
150 rpm. The time taken for tablet detachment or for complete disappearance from the 
mucosa was considered as the mucoadhesion period (19).
In vitro mucoadhesive strength
The mucoadhesive strength was determined using a modified physical balance that 
measures the force of tablet detachment from the mucosal surface. Briefly, one arm of the 
balance was used to hold the tablet between 2 rabbit mucosa pasted on glass slides. Both 
faces of the tablet were wetted with a drop of phosphate buffer (pH 6.8) and pressed gently 
for 10 seconds before placing it between the mucosae. One glass slide was stationary and 
was fixed to the base, while the other was mobile and attached to the threaded arm of the 
pan. The minimum weight required to detach the tablet from the mucosa was considered 
as the mucoadhesive strength (20). The values for mucoadhesive strength were expressed 
in terms of Force (N) using Eq. 1.




s×  Eq. 1
Swelling index
The swelling index was measured by placing weighed tablets in a Petri dish contain-
ing 10 mL of phosphate buffer (pH 6.8). The mass gain of an individual tablet was mea-
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sured at different time intervals, initially at 0.5 h and then after each hour up to 4 h and 
then at 10 h. Swelling indices were measured using Eq. 2.
 Swellability index = 




×  Eq. 2
In vitro drugs release
Drug release studies were carried out using a USP type II (paddle) apparatus (ERWEKA 
DT-700) according to the method previously described in the literature (21). Experimental 
conditions adopted for dissolution studies include phosphate buffer (pH 6.8) (500 mL) 
maintained at 37 ± 5 °C with a paddle rotating speed of 50 rpm. Aliquots of 5 mL were 
withdrawn at selected time intervals (0.5, 1.0 and 3.0 h) and replaced with fresh dissolution 
medium to maintain the sink condition. The quantity of drug release over time was deter-
mined by the HPLC method. Since the solubility of lidocane hydrochloride and flurbipro-
fen is 4.1 and 0.0249 mg mL–1, respectively, 500 mL of dissolution media was enough to 
maintain the sink conditions.
Each sample was analysed for drug content using an HPLC system (Shimadzou, LC10 
ATVP). The elution was carried out using the mobile phase (aqueous solution of sodium 
heptane sulphonate anhydrous, sodium phosphate dibasic and EDTA/acetonitrile (6:4, 
V/V)). The flow rate under ambient conditions was 1.2 mL min–1. Drug concentration was 
determined by calculating the area under the curve of two absorption peaks (λ = 210 nm) 
obtained at the retention time at 1.5 min and 5.8 min for LID and FLB, respectively (Fig. 1).
A calibration curve of both drugs in phosphate buffer solution (pH 6.8) was construct-
ed by recording the absorption peaks of standard solutions containing 1, 5, 10, 20, 40, 60, 
80 and 100 µg mL–1 of each drug. Calibration curves for both drugs showed linearity over 
a range of 1 to 100 µg mL–1 (R2 = 0.999). The regression equation for flurbiprofen was found 
to be y = 42516x + 27660 while that for lidocaine HCl was  y = 20231x + 26075. The calibration 
curves manifest a limit of quantitation of 0.12 and 1.11 µg mL–1 and limit of detection of 
Fig. 1. Representative HPLC chromatogram for flurbiprofen and lidocaine hydrochloride.
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0.03 and 0.33 µg mL–1 for LID and FLB, respectively. The coefficient of variation for intra-
assay and inter-assay precision was less than or equal to 5.42 % and the accuracy was be-
tween 95 and 101 %.
Optimization of mucoadhesive formulation by the artificial neural network approach
To study relative effects of HPMC and SA on physicochemical parameters, ANN, i.e., 
the NeuralPower® version 3.1, was employed using a „what if” command. Quick propaga-
tion (QP) method was used for the learning algorithm with Tanh as transfer function. 
Multilayer perceptron (MLP) structure was used in the study where the class of structure 
was feed forward. The total number of input, output and hidden layers was 2, 9 and 1, 
respectively (Fig. 2). Surface responses were generated for relative excipient importance 
towards physicochemical parameters.
Results from the physicochemical parameters of initial nine formulations were the 
basis for using a ‘what if’ approach in ANN for the prediction of the best levels of polymers 
to achieve an optimized buccoadhesive formulation. Surface responses were then gener-
ated for relative excipient importance towards physicochemical parameters as followed in 
a similar study (21). ANN predicted results were validated by preparing a confirmation 
formulation (F10) using the quantity of ingredients as described in Table I. Tablets were 
then prepared by the same method as above, i.e., by the direct compression method. Tab-
lets were tested for hardness, weight variation, friability, surface pH, mucoadhesive 
strength, mucoadhesion time, swellability index and in vitro release of both drugs.
RESULTS AND DISCUSSION
Results of the physical parameters such as weight variation, hardness, friability, mu-
coadhesive strength and time are shown in Table II. All the tablet formulations showed 
acceptable values of these parameters, based on BP (2011) specification.
Fig. 2. Structure of ANN employed in this study.
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The surface pH of the buccal tablet should not disturb the micro-environment of buc-
cal mucosa, body functions and physiological features of the mucosa. Low pH can damage 
the mucous membrane, so an acceptable range of 5.8–7.0 is ideal (22). All formulations 
demonstrated slight variations in surface pH and were generally acidic (Table II). The 
surface pH of formulations F4 and F5 were within the acceptable range (pH 5.8–7.0). The 
acidic nature of the majority of formulations is ascribed to the release of LID HCl.
The mucoadhesive strength and mucoadhesion time of each formulation are meas-
ures of capability to adhere to the buccal cavity and also relate to drug release (for localised 
effect). Both parameters depend upon the type and concentration of polymers used in the 
formulation (19). In general, greater values are deemed favourable for tablet attachment to 
the mucosa (21). The results show that formulations containing greater quantities of HPMC 
(F7 to F9) exhibit higher mucoadhesive strength (~0.2 N) and mucoadhesive time (~9 h) 
compared to those containing reduced quantities of these excipients (F1 to F6, see Table 
III). Formulations demonstrating mucoadhesive strength > 0.15 N (F5 to F9) were selected 
for in vitro release studies.
Swelling index is a quantitative determination of the degree of water uptake by the 
tablet. In general, the swellability index for F1-F4 decreased over time (up to 10 h) relative 
to the initial dry tablet weight (Table III). The decrease in swellability index is explained 
by LID solubility in water, which causes it to diffuse out of the matrix, thereby decreasing 
the tablet mass over time.
The release of both FLB and LID from different formulations is given in Fig. 3. Among 
formulations F5 to F9, the release of FLB in the first 0.5 h was highest from formulation F6 
(~ 85 %) while it was lowest from formulation F9 (~40 %). However, after 1 h, all five formu-
lations exhibited almost complete release of FLB (Fig. 3a).
In contrast, the release of LID was slow (compared to FLB), with all formulations ex-
cept F6 releasing from 10–30 % within 0.5 h. The release of LID from formulation F6 over 
















F1 495.6 ± 3.69 6.0 0.455 0.11 5.02 4.21
F2 495.4 ± 4.17 6.2 0.397 0.14 4.35 4.62
F3 499.0 ± 3.82 6.7 0.578 0.13 4.41 6.33
F4 496.0 ± 4.60 6.6 0.688 0.14 6.98 5.81
F5 496.2 ± 4.84 6.9 0.447 0.15 6.76 6.94
F6 497.4 ± 3.90 6.3 0.621 0.16 4.25 6.40
F7 497.2 ± 4.34 6.6 0.63 0.22 5.64 7.52
F8 497.1 ± 4.06 6.5 0.572 0.21 5.02 9.50
F9 497.7 ± 3.77 7.0 0.402 0.17 4.92 9.00
Average mass was calculated as mean ± SD of 10 determinants.
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the same time period was ~85 %. At 1 h, all formulations showed almost complete dissolu-
tion (Fig. 3b). The results for in vitro release suggest that drug release from formulations 
depended upon the ratio of HPMC to SA. The formulation with higher HPMC to SA ratio, 
i.e., F6, showed higher release of FLB and LID compared the formulations with reverse 
ratio values (23). In this instance, formulation F6, due to its low mucoadhesive strength and 
mucoadhesion time, was not considered useful for providing analgesic and anaesthetic 
action locally. The ANN approach was applied to obtain a formulation with optimum drug 
release, mucoadhesive strength and mucoadhesion time.
Data for physicochemical properties, in vitro mucoadhesive strength, mucoadhesion 
time, surface pH (Table II), swellability index (Table III) and in vitro drug release (Fig. 1) 
were used to analyse the combined effect of HPMC and SA. ANN generated surface plots 
Fig. 3. Plot showing in vitro release of: a) flurbiprofen and b) lidocaine hydrochloride from various 
formulations at different time intervals. Formulations in the preliminary study (F1-F4) were not test-
ed for in vitro release.
Table III. Swelling indices (%) of tablet formulations at different time intervals
Formula-
tion
Swelling index at different time intervals
Time (h)
0.5 1 2 3 4 10
F1 210.8 207.6 198.2 176.9 167.2 63.9
F2 165.1 152.2 145.1 139.6 132 132
F3 157.4 142.9 134.4 126.9 129.7 70.3
F4 127.3 106.4 109.8 100.4 96.2 107.6
F5 63.9 54.2 62.7 63.5 60.7 86.7
F6 66.3 60.1 55.8 55.2 59.4 102.5
F7 55.7 53.5 51.3 53.5 53.5 55.3
F8 51.7 50.6 48.8 50.6 52.9 59.4
F9 41.3 40.5 42.1 42.3 44.3 71.9
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describing the relative importance of HPMC and SA for physicochemical properties are 
shown in Fig. 3. Change in colour (24) from blue to red shows an increasing effect of these 
polymers. Here, red colour indicates a more prominent effect than blue colour. As shown 
in Fig. 4, HPMC imparted a stronger impact on the in vitro LID release, mucoadhesive 
strength, mucoadhesive time and pH compared to SA. Conversely, in vitro FLB release and 
swellability index parameters were more related to SA, Fig. 4c and f.
As predicted by ANN, formulation F10 (Table I) was prepared and evaluated (through 
experimentation and observed outcomes) (21) for all the physiochemical properties (Table 
IV).
Fig. 4. ANN predicted relative importance of HPMC and SA for: a) mucoadhesive strength, b) muco-
adhesion time, c) in vitro release FLB, d) in vitro release LID, e) surface pH and f) swellability index at 10 h.
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For formulation F10, predicted outcomes for mucoadhesive strength and mucoadhe-
sion time were in close proximity to the actually observed outcomes. The release of FLB 
and LID from F10 (Fig. 5) was gradual over a 3 h period, suggesting prolonged action of 
the drug at the site of action (buccal cavity). Thus the prepared formulation can be used 
for the relief of dental pain for a longer period of time by acting locally.
Release kinetics of formulation F10 show that LID and FLB followed the Korsmeyer-
Peppas model where n = 1.340, explicating a special type (n > 0.89), i.e., super case II release. 
Table IV. Comparison of the properties of predicted vs. experimatal formulation
Parameters Predicted Observed
Mucoadhesive strength (N) 0.285 0.286
Surface pH 5.44 5.44
Mucoadhesion time (h) 8.99 9.2
Swellability at 30 min (%) 38.13 39.4
Swellability at 1 h (%) 37.66 38.8
Swellability at 2 h (%) 39.04 39
Swellability at 3 h (%) 40.63 41.6
Swellability at 4 h (%) 38.29 39.4
Swellability at 10 h (%) 41.66 42.4
In vitro % release at 0.5 h (Lidocaine HCl) 11.64 11.80
In vitro release at 1 h (%) 18.01 17.91
In vitro release at 3 h (%) 88.92 88.90
In vitro release at 0.5 h (%) (Flurbiprofen) 36.69 37.12
In vitro release at 1 h (%) 61.87 62.74
In vitro release at 3 h (%) 100.28 100.45
Fig. 5. The plot showing the release of flurbiprofen and lidocaine from optimized formulation, F10.
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This is probably due to the influx of fluid into the tablet matrix causing the swelling and 
subsequent diffusion of the drug from the matrix into the dissolution medium (25, 26). 
These results are supported by the microscopic observation (Fig. 6) showing disintegration 
and subsequent cleavage of particles from the „swelled tablet” eliciting erosion of the 
matrix (27, 28).
CONCLUSIONS
Novel mucoadhesive dental analgesic tablets containing FLB and LID HCl were pre-
pared using HPMC and SA as mucoadhesive agents. The release of both active ingredients 
was also found to be dependent on the relative ratio of HPMC to SA. The formulation 
containing a higher proportion of HPMC to SA showed an extended release profile. ANN 
assisted factor analysis showed that the HPMC imparted a stronger impact on the in vitro 
LID release, mucoadhesive strength, mucoadhesive time and pH compared to SA. Con-
versely, in vitro FLB release and swellability index parameters were more related to SA. 
ANN predicted optimized formulation provides appropriate in vitro mucoadhesive 
strength (0.286 N), mucoadhesion time (9.2 h) and drug release > 85 %, which supports the 
application of the in silico tool in formulation development.
Ethical approval for using mucosal membrane was obtained from the Animal Ethics 
Committee (Approval No. AEC/UCP/1031/4313, dated 15/09/2014), University College of 
Pharmacy, University of the Punjab, Lahore, Pakistan.
Fig. 6. Diagrammatic illustration of matrix and gel formation, breaking of small gel particles and 
matrix erosion during swelling of F10 at different time intervals when placed in 20 mL phosphate 
buffer solution, pH = 6.8 (taken with a Stereo zoom microscope).
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